Methiopropamine

coronary artery disease, cardiomyopathy, arrhythmias, uncontrolled hypertension

MPA's catecholaminergic mechanism produces dose-dependent vasoconstriction and tachycardia. A chronic mouse model demonstrated myocardial ischemia and 40% sudden death attributed to cardiovascular events (Foti et al. 2019). In 11 analytically confirmed human cases, tachycardia was present in 91% (White et al. 2019). Pre-existing cardiovascular disease dramatically increases the risk of acute cardiac events.

epilepsy, seizure disorders

Catecholaminergic stimulants are known to reduce seizure threshold. While no MPA-specific data on seizure risk have been published, the mechanism of action (norepinephrine-dopamine reuptake inhibition) predicts this risk by structural analogy to methamphetamine and other stimulants.

psychotic disorders, bipolar disorder, schizophrenia

Acute psychosis, paranoid delusions, auditory and visual hallucinations, and incoherent speech are documented in MPA intoxication cases (Daveluy et al. 2016; White et al. 2019). Hallucinations occurred in 45% and confusion in 64% of hospitalized patients. Individuals with pre-existing psychotic or bipolar disorders face elevated risk of symptom exacerbation.

chronic kidney disease, renal impairment

Raised creatine kinase (a marker of rhabdomyolysis) was found in 64% of hospitalized MPA patients (White et al. 2019), though polydrug confounding is possible. A chronic mouse model demonstrated renal ischemic-necrotic lesions (Foti et al. 2019). Pre-existing renal impairment increases vulnerability to further nephrotoxic insult.

pregnancy, lactation

No reproductive toxicity data exist for MPA. Catecholaminergic stimulants are generally contraindicated during pregnancy due to vasoconstriction-mediated risks to placental perfusion and fetal development. This contraindication is inferred from class-level evidence, not MPA-specific data.

MAOI use

Concurrent use of monoamine oxidase inhibitors with MPA (a norepinephrine-dopamine reuptake inhibitor) poses a risk of hypertensive crisis. This contraindication is inferred from the standard catecholaminergic stimulant class interaction and has not been directly studied for MPA.

SSRI use, SNRI use, tramadol use, serotonergic medication use

Although MPA is a weak serotonin reuptake inhibitor (SERT IC₅₀ >25 µM), combination with potent serotonergic agents poses additive serotonin toxicity risk, particularly at higher MPA doses. DrugWise specifically warns that combining MPA with MDAI or 5-IAI may produce serotonin toxicity including hyperthermia, hypertension, and rhabdomyolysis potentially leading to fatal renal failure.